335 related articles for article (PubMed ID: 24344027)
1. Combination of p16 levels and pre-radiotherapy factors predicts outcome in patients treated for oropharyngeal carcinoma.
Bar-Ad V; Wang ZX; Leiby B; Tuluc M
J BUON; 2013; 18(4):982-8. PubMed ID: 24344027
[TBL] [Abstract][Full Text] [Related]
2. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
[TBL] [Abstract][Full Text] [Related]
3. Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques.
Leeman JE; Li JG; Pei X; Venigalla P; Zumsteg ZS; Katsoulakis E; Lupovitch E; McBride SM; Tsai CJ; Boyle JO; Roman BR; Morris LGT; Dunn LA; Sherman EJ; Lee NY; Riaz N
JAMA Oncol; 2017 Nov; 3(11):1487-1494. PubMed ID: 28542679
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.
Rischin D; Young RJ; Fisher R; Fox SB; Le QT; Peters LJ; Solomon B; Choi J; O'Sullivan B; Kenny LM; McArthur GA
J Clin Oncol; 2010 Sep; 28(27):4142-8. PubMed ID: 20697079
[TBL] [Abstract][Full Text] [Related]
5. Influence of HPV-status on survival of patients with tonsillar carcinomas (TSCC) treated by CO
Hoffmann M; Quabius ES; Tribius S; Gebhardt S; Görögh T; Hedderich J; Huber K; Dunst J; Ambrosch P
Cancer Lett; 2018 Jan; 413():59-68. PubMed ID: 29100961
[TBL] [Abstract][Full Text] [Related]
6. p16 positive oropharyngeal squamous cell carcinoma:an entity with a favorable prognosis regardless of tumor HPV status.
Lewis JS; Thorstad WL; Chernock RD; Haughey BH; Yip JH; Zhang Q; El-Mofty SK
Am J Surg Pathol; 2010 Aug; 34(8):1088-96. PubMed ID: 20588174
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
8. Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status.
Maqsood S; Jameson MB; De Groot C; Hartopeanu C; Yasin NABHM; Thotathil Z
Cancer Rep (Hoboken); 2018 Jun; 1(1):e1001. PubMed ID: 32729235
[TBL] [Abstract][Full Text] [Related]
9. Tumor cell anaplasia and multinucleation are predictors of disease recurrence in oropharyngeal squamous cell carcinoma, including among just the human papillomavirus-related cancers.
Lewis JS; Scantlebury JB; Luo J; Thorstad WL
Am J Surg Pathol; 2012 Jul; 36(7):1036-46. PubMed ID: 22743286
[TBL] [Abstract][Full Text] [Related]
10. Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma.
Nakano T; Yamamoto H; Nakashima T; Nishijima T; Satoh M; Hatanaka Y; Shiratsuchi H; Yasumatsu R; Toh S; Komune S; Oda Y
Hum Pathol; 2016 Apr; 50():51-61. PubMed ID: 26997438
[TBL] [Abstract][Full Text] [Related]
11. A quantitative histomorphometric classifier (QuHbIC) identifies aggressive versus indolent p16-positive oropharyngeal squamous cell carcinoma.
Lewis JS; Ali S; Luo J; Thorstad WL; Madabhushi A
Am J Surg Pathol; 2014 Jan; 38(1):128-37. PubMed ID: 24145650
[TBL] [Abstract][Full Text] [Related]
12. Tumor volume as a prognostic marker in p16-positive and p16-negative oropharyngeal cancer patients treated with definitive intensity-modulated radiotherapy.
Carpén T; Saarilahti K; Haglund C; Markkola A; Tarkkanen J; Hagström J; Mattila P; Mäkitie A
Strahlenther Onkol; 2018 Aug; 194(8):759-770. PubMed ID: 29774396
[TBL] [Abstract][Full Text] [Related]
13. Long term results of postoperative Intensity-Modulated Radiation Therapy (IMRT) in the treatment of Squamous Cell Carcinoma (SCC) located in the oropharynx or oral cavity.
Hoffmann M; Saleh-Ebrahimi L; Zwicker F; Haering P; Schwahofer A; Debus J; Huber PE; Roeder F
Radiat Oncol; 2015 Dec; 10():251. PubMed ID: 26637471
[TBL] [Abstract][Full Text] [Related]
14. p16 Expression as a predictive biomarker of hypoxic cell-sensitizing agents in oropharyngeal cancer.
Chung CH; Raben D
J Clin Oncol; 2010 Sep; 28(27):4103-4. PubMed ID: 20697096
[No Abstract] [Full Text] [Related]
15. Risk profiling based on p16 and HPV DNA more accurately predicts location of disease relapse in patients with oropharyngeal squamous cell carcinoma.
Rasmussen JH; Grønhøj C; Håkansson K; Friborg J; Andersen E; Lelkaitis G; Klussmann JP; Wittekindt C; Wagner S; Vogelius IR; von Buchwald C
Ann Oncol; 2019 Apr; 30(4):629-636. PubMed ID: 30657857
[TBL] [Abstract][Full Text] [Related]
16. Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: clinical outcomes and patterns of failure.
Daly ME; Le QT; Maxim PG; Loo BW; Kaplan MJ; Fischbein NJ; Pinto H; Chang DT
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1339-46. PubMed ID: 19540068
[TBL] [Abstract][Full Text] [Related]
17. Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume.
Chao KS; Ozyigit G; Blanco AI; Thorstad WL; Deasy JO; Haughey BH; Spector GJ; Sessions DG
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):43-50. PubMed ID: 15093897
[TBL] [Abstract][Full Text] [Related]
18. Impact of p16, p53, smoking, and alcohol on survival in patients with oropharyngeal squamous cell carcinoma treated with primary intensity-modulated chemoradiation.
Broglie MA; Soltermann A; Rohrbach D; Haile SR; Pawlita M; Studer G; Huber GF; Moch H; Stoeckli SJ
Head Neck; 2013 Dec; 35(12):1698-706. PubMed ID: 23508511
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of intensity-modulated radiotherapy versus conventional radiotherapy for hypopharyngeal cancer.
Mok G; Gauthier I; Jiang H; Huang SH; Chan K; Witterick IJ; O'Sullivan B; Waldron JN; Bayley AJ; Cho BC; Cummings BJ; Dawson LA; Hope AJ; Kim JJ; Ringash J
Head Neck; 2015 May; 37(5):655-61. PubMed ID: 24590756
[TBL] [Abstract][Full Text] [Related]
20. Reevaluation of postoperative radiation dose in the management of human papillomavirus-positive oropharyngeal cancer.
Chin RI; Spencer CR; DeWees T; Hwang MY; Patel P; Sinha P; Gay HA; Haughey BH; Nussenbaum B; Adkins DR; Lewis JS; Thorstad WL
Head Neck; 2016 Nov; 38(11):1643-1649. PubMed ID: 27152851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
